ABSTRACT
Objective To discuss the Survivin protein expression in different salivary gland tumor.(Methods)This experiment was based on tissue chip technology.Expression of Survivin protein in the salivary gland tumor was analyzed with immunohistochemical methods.Results ① Survivin expression showed significant difference in the salivary gland benign and malignant tumors(P0.05).The gland around the malignant tumor showed diversity compared with malignant tumor(P0.05).Conclusion Survivin expression has correlation with the relay tumor canceration,and the gland around malignant tumor has correlation with occurrence,progress,prognosis in the salivary gland malignant tumor,and it is a reliable marker of earlier period diagnosis and prognosis of the malignant tumor of salivary gland.
ABSTRACT
Objective To study the expression of survivin in malignant pleomorphic adenoma,relay pleomorphic adenoma and pleomorphic adenoma.Methods The transcription and interpretation of urvivin mRNA in the salivary gland tumor were analyzed via immunohistochemistry and in situ hybridization methods.Results Survivin mRNA expression and protein expression were almost the same in malignant pleomorphic adenoma,relay pleomorphic adenoma and pleomorphic adenoma.But they were different in the gland around the malignant pleomorphic adenoma.There was a significant difference of Survivin mRNA and protein expression in pleomorphic adenoma and malignant pleomorphic adenoma,and relay pleomorphic adenoma.The expressions were almost the same in relay and malignant pleomorphic adenoma.Conclusion The expression of survivin mRNA and protein is increased in pleomorphic adenoma and may be involved in the onset and progression of pleomorphic adenoma.It indicates that mRNA is relatively stable in the mRNA transcription and protein interpretation in malignant pleomorphic adenoma,and it is also showed earlier in gene amplification than in protein expression of the malignant tumor in the initial stage of malignant pleomorphic adenoma.Survivin can be a new diagnostic/therapeutic target in pleomorphic adenoma.